Colin Hill is a leading voice in AI and precision medicine and brings impressive leadership experience in developing and commercializing AI solutions and discoveries in biopharmaceutical drug discovery and development and in managed care industries. Colin currently serves on the board of Centrexion Therapeutics, a biotech company focused on developing and commercializing non-opioid, non-addictive chronic pain drugs.
Colin previously served on the boards of Biotelemetry Inc. (NASDAQ: BEAT), the leading mobile health information company (acquired by Philips in 2021), and PPD Inc. (NASDAQ: PPD), a leading global contract research organization (acquired by Thermo in 2021), and was a founding member of the Board of Directors of AesRx, a biopharmaceutical company dedicated to the development of new treatments for sickle cell disease (acquired by Baxter in 2014).
He was also a founding board member of TMed (Transforming Medicine: The Elizabeth Kauffman Institute), a non-profit foundation (501c3) dedicated to the advancement of personalized medicine. In 2016, he was appointed by Massachusetts Governor Charlie Baker to the Massachusetts Digital Health Council. Colin was the founding Chairman of O’Reilly Media’s Strata Rx in 2012, the first healthcare big data conference in the industry. In 2004, Colin was named to MIT Technology Review’s TR100 list of the top 100 innovators in the world under the age of 35.
He is a frequent speaker at national and international scientific and industry conferences and has appeared in numerous publications and television programs, including The Wall Street Journal, CNBC Morning Call & SquawkBox, Nature, Boston Globe, Politico, Forbes, Wired, and The Economist.
